



ASX/NASDAQ Media Release

17 June 2008

PHARMAXIS ESTABLISHES NAMED PATIENT PROGRAM FOR BRONCHITOL

Pharmaxis (ASX: PXS, NASDAQ: PXSL) today announced the appointment of IDIS Limited to manage and provide eligible patients worldwide with access to Bronchitol through a Named Patient Program.

The program will allow patients who are unable to participate in current Pharmaxis clinical trials but who are considered by their physician to be suffering from a clinical condition for which no satisfactory authorised alternative exists, to receive access to Bronchitol on a named patient basis.

The program will establish a common approach to the use and distribution of Bronchitol and the eligibility of patients.

"IDIS is a partner of choice for major global pharmaceutical companies in providing ethical named patient access to medicines in countries where the product is yet to be authorised," said Pharmaxis CEO Alan Robertson.

"Bronchitol will be made available to people with a chronically or seriously debilitating, or life threatening condition who cannot be treated satisfactorily by an authorized medicine.

"IDIS manages Named Patient Programs in over 100 countries, and is recognised for its rigorous capture of pharmacovigilance information and quality doctor education programs.

"We are pleased to be able to offer the option of Bronchitol to physicians with patients in urgent need," said Dr Robertson.

Bronchitol is in final clinical trials for the treatment of the chronic lung conditions cystic fibrosis and bronchiectasis. The U.S. Food and Drug Administration has granted Bronchitol fast track status and it is designated as an orphan drug in the U.S. and Europe.

- Ends -

SOURCE: Pharmaxis Ltd, Sydney, Australia
CONTACT: Alan Robertson - Chief Executive Officer
Ph: +61 2 9454 7200 or email alan.robertson@pharmaxis.com.au

Further information on the Program is available from IDIS Limited:
Tel: +44 1932 824000
E-mail: gma@idispharma.com

RELEASED THROUGH:

Australia:

Virginia Nicholls, phone +61 417 610 824 or email virginia.nicholls@pharmaxis.com.au

United States:

Brandon Lewis, Trout Group, phone +1 646 378 2915 or email blewis@troutgroup.com

About Pharmaxis

Pharmaxis (ACN 082 811 630) is a specialist pharmaceutical company involved in the research, development and commercialization of therapeutic products for chronic respiratory and immune disorders. Its development pipeline of products includes Aridol for the management of asthma, Bronchitol for cystic fibrosis, bronchiectasis and chronic obstructive pulmonary disease (COPD) and PXS64 for the treatment of multiple sclerosis.

Founded in 1998, Pharmaxis is listed on the Australian Stock Exchange (symbol PXS), and on NASDAQ Global Market (symbol PXSL). The company is headquartered in Sydney at its TGA-approved manufacturing facilities. For more information about Pharmaxis, go to www.pharmaxis.com.au or contact Investor Relations on phone +61 2 9454 7200.

About IDIS

IDIS is the leading authority in the field of named-patient medicine sourcing and supply. Having built an impressive reputation as a reliable and ethical source of named-patient medicines, IDIS prides itself on helping to provide a lifeline to patients and the medical profession. IDIS supports pharmacists and physicians globally by sourcing and supplying medicines on an ethical named-patient basis. IDIS works in partnership with the pharmaceutical and biotechnology industry to establish and deliver pre-launch named-patient management programmes, develop solutions for a discontinued brand, manage temporary supply problems and source and supply medicines for clinical trials. IDIS has specialist in-house expertise in legal and regulatory requirements, technical and clinical support, pharmacovigilance, import/export requirements and distribution and storage to deal with the complexities associated with handling named-patient medicines in an ethical and professional manner.

About Bronchitol

Pharmaxis Ltd is developing Bronchitol for the management of chronic obstructive lung diseases including cystic fibrosis, bronchiectasis and chronic bronchitis. Bronchitol is a proprietary formulation of mannitol administered in a convenient hand-held, pocket-sized inhaler. Its formulation as a dry powder with four-way action helps restore normal lung clearance mechanisms. Clinical studies have shown Bronchitol to be safe, effective and well tolerated in stimulating mucus hydration and clearance in people with chronic obstructive lung diseases. In particular, Bronchitol has been shown to increase mucus clearance from the lungs and significantly improve quality of life for people with bronchiectasis. Additional short term studies have also shown Bronchitol to improve lung function in people affected by cystic fibrosis.

Forward-Looking Statements

The statements contained in this media release that are not purely historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements in this media release include statements regarding our expectations, beliefs, hopes, goals, intentions, initiatives or strategies, including statements regarding the potential for Aridol and/or Bronchitol. All forward-looking statements included in this media release are based upon information available to us as of the date hereof, and we assume no obligation to update any such forward-looking statement as a result of new information, future events or otherwise. We can not guarantee that any product candidate will receive FDA or other regulatory approval or that we will seek any such approval. Factors that could cause or contribute to such differences include, but are not limited to, factors discussed in the "Risk Factors and Other Uncertainties" section of our Form 20-F lodged with the U.S. Securities and Exchange Commission.